Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression

Journal of Clinical Psychiatry

Volumn 66, Issue 6, 2005, Pages 708-716

  Murray, Veronica ^a   Von Arbin, Magnus ^a   Bartfai, Aniko ^b   Berggren, Anna Lena ^c   Landtblom, Anne Marie ^d   Lundmark, Jöns ^d   Näsman, Per ^e   Olsson, Jan Edvin ^d   Samuelsson, Margareta ^f   Terént, Andreas ^c   Varelius, Riitta ^f   Åsberg, Marie ^a   Mårtensson, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESZOPICLONE; FLUOXETINE; NORTRIPTYLINE; PLACEBO; SERTRALINE; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; EMOTIONAL DISORDER; EMOTIONAL DISTRESS SCALE; EMOTIONAL INDIFFERENCE; EMOTIONAL STRESS; EMOTIONALITY; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED DREAM ACTIVITY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REDUCED SLEEP DURATION; SLEEP DISORDER; STROKE; SWEDEN; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 21744444273     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0606     Document Type: Article

References (42)

1. Aben I, Verhey F, Honig A, et al. Research into the specificity of depression after stroke: a review of an unresolved issue. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:671-689
2. Berg A, Palomäki H, Lehtihalmes M, et al. Poststroke depression: an 18-month follow-up. Stroke 2003;34:138-143
3. Morris PL, Shields RB, Hopwood MJ, et al. Are there two depressive syndromes after stroke? J Nerv Ment Dis 1994;182:230-234
4. González-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995;7:547-560
5. Morris PL, Robinson RG, Andrzejewski P, et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150: 124-129
6. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001;32:696-701
7. Jorge RE, Robinson RG, Arndt S, et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160:1823-1829
8. Stenager EN, Madsen C, Stenager E, et al. Suicide in patients with stroke: epidemiological study. BMJ 1998;316:1206
9. Ahlsiö B, Britton M, Murray V, et al. Disablement and quality of life after stroke. Stroke 1984;15:886-890
10. Golomb BA, Vickery BG, Hays RD. A review of health-related quality of life measures in stroke. Pharmacoeconomics 2001;2:155-185
11. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984;1:297-300
12. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157:351-359
13. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-1104
14. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31: 1829-1832
15. Rasmussen A, Lunde M. Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients [Erratum in Psychosomatics 2004;45:91]. Psychosomatics 2003;44:216-221
16. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol 1986;43:763-765
17. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211-1214
18. Hackett M, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2004;2:CD003437
19. World Health Organization. Cerebrovascular diseases: prevention, treatment, and rehabilitation. WHO Org Techn Rep Ser: 1971
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association: 1994
21. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
22. Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 1987;110:1045-1059
23. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526
24. Stegmayr B, Asplund K, Hulter-Åsberg K, et al. Stroke units in their natural habit: can results of randomized trials be reproduced in routine clinical practice? Riks-Stroke Collaboration. Stroke 1999;30:709-714
25. Glader E-L. Stroke Care in Sweden: Hospital Care and Patient Follow-Up Based on Riks-Stroke, the National Quality Register for Stroke Care [dissertation]. Umeå, Sweden: University Medical Dissertations New serie No 838, Umeå University; 2003
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
27. Wiholm BE, Åsberg M, Jacobsen K, et al. A rating scale for emotional distress in patients with malignant diseases. Acta Psychiatr Scand 1984; 70:378-388
28. Rödén-Jüllig Å, Britton M, Gustafsson C, et al. Validation of four scales for the acute stage of stroke. J Intern Med 1994;236:125-136
29. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-65
30. Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-79
31. Montgomery SA. The failure of placebo-controlled studies. ECNP Consensus Meeting. September 13, 1997, Vienna, Austria. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999;9:271-276
32. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12: 323-331
33. Åberg-Wistedt A, Ågren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000;20:645-652
34. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160: 1277-1285
35. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995;7:89-104
36. Preskom SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129-141
37. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet 2000;356:122-126
38. Carola A, Staub F, Bogousslavsky J. Emotions, behaviours and mood changes in stroke. Curr Opin Neurol 2002;15:57-69
39. Kemp AH, Gray MA, Silberstein RB, et al. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage 2004;22: 1084-1096
40. House AO, Hackett ML, Anderson CS, et al. Pharmaceutical interventions for emotionalism after stroke. In: The Cochrane Library, Issue 3, 2004. Chichester. England: Wiley
41. Burns A, Russell E, Stratton-Powell H, et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999;14:681-685
42. Turner-Stokes L. Poststroke depression: getting the full picture. Lancet 2003;361:1757-1758